Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma

Allogeneic CAR Cell Therapy—More Than a Pipe Dream

(2021) Kenneth J. Caldwell et al.   Frontiers in Immunology

Function of γδ T cells in tumor immunology and their application to cancer therapy

(2021) Jang Hyun Park et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia

(2021) Rajkumar Ganesan et al.   LEUKEMIA

Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy

(2021) Weiqin Jiang et al.   Frontiers in Immunology

Dichotomous and stable gamma delta T-cell number and function in healthy individuals

(2021) Lingling Ou et al.   Journal for ImmunoTherapy of Cancer

Cancer immunotherapy with γδ T cells: many paths ahead of us

(2020) Dieter Kabelitz et al.   Cellular & Molecular Immunology

The adenosine pathway in immuno-oncology

(2020) Bertrand Allard et al.   Nature Reviews Clinical Oncology

Characteristic of TIGIT and DNAM-1 Expression on Foxp3+ γδ T Cells in AML Patients

(2020) Zhenyi Jin et al.   Biomed Research International

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia

(2020) Meir Rozenbaum et al.   Frontiers in Immunology

T cell optimization for graft-versus-leukemia responses

(2020) Melinda A. Biernacki et al.   JCI Insight

Tumor resistance mechanisms and their consequences on γδ T cell activation

(2020) Daniela Wesch et al.   IMMUNOLOGICAL REVIEWS

Decreased Frequency of Intestinal CD39+ γδ+ T Cells With Tissue-Resident Memory Phenotype in Inflammatory Bowel Disease

(2020) Jana Libera et al.   Frontiers in Immunology

TIGIT in cancer immunotherapy

(2020) Joe-Marc Chauvin et al.   Journal for ImmunoTherapy of Cancer

TIM-3 pathway dysregulation and targeting in cancer

(2020) Amer M Zeidan et al.   Expert Review of Anticancer Therapy

γδ T Cell Update: Adaptate Orchestrators of Immune Surveillance

(2019) Adrian C. Hayday   JOURNAL OF IMMUNOLOGY

TOX is a critical regulator of tumour-specific T cell differentiation

(2019) Andrew C. Scott et al.   NATURE

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

(2019) Omar Khan et al.   NATURE

Tim-3 suppresses the killing effect of Vγ9Vδ2 T cells on colon cancer cells by reducing perforin and granzyme B expression

(2019) Xiaomi Li et al.   EXPERIMENTAL CELL RESEARCH

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

(2019) Sarwish Rafiq et al.   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation

(2018) Anna Capsomidis et al.   MOLECULAR THERAPY

Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression

(2018) Barbara Castella et al.   Frontiers in Immunology

Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias

(2018) Vito Pistoia et al.   Frontiers in Immunology

γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion

(2018) Elena Lo Presti et al.   Frontiers in Immunology

Tissue Adaptations of Memory and Tissue-Resident Gamma Delta T Cells

(2018) Camille Khairallah et al.   Frontiers in Immunology

PD-1 signaling modulates interferon-γ production by Gamma Delta (γδ) T-Cells in response to leukemia

(2018) Timm Hoeres et al.   OncoImmunology

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

(2017) Bertrand Allard et al.   IMMUNOLOGICAL REVIEWS

Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor

(2017) Jonathan Fisher et al.   MOLECULAR THERAPY

Key Features of Gamma-Delta T-Cell Subsets in Human Diseases and Their Immunotherapeutic Implications

(2017) Myriam Lawand et al.   Frontiers in Immunology

PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?

(2017) Sylvain Simon et al.   OncoImmunology

Tumor-infiltrating CD39+ γδTregs are novel immunosuppressive T cells in human colorectal cancer

(2017) Guoming Hu et al.   OncoImmunology

IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population

(2017) Clément Barjon et al.   OncoImmunology

CD27 - CD45 + γδ T cells can be divided into two populations, CD27 - CD45 int and CD27 - CD45 hi with little proliferation potential

(2016) Kosuke Odaira et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

(2016) Donnele Daley et al.   CELL

T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients

(2016) Y. Kong et al.   CLINICAL CANCER RESEARCH

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection

(2016) Matthias Hoffmann et al.   PLoS Pathogens

BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia

(2016) Audrey Benyamine et al.   OncoImmunology

   T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-  +/CD19+ lymphocytes

(2015) I. Airoldi et al.   BLOOD

Myeloid molecular characteristics of human γδ T cells support their acquisition of tumor antigen-presenting capacity

(2015) Masato Muto et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients

(2015) Joe-Marc Chauvin et al.   JOURNAL OF CLINICAL INVESTIGATION

IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis

(2015) Seth B. Coffelt et al.   NATURE

The prognostic landscape of genes and infiltrating immune cells across human cancers

(2015) Andrew J Gentles et al.   NATURE MEDICINE

Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells

(2014) Martin Wilhelm et al.   Journal of Translational Medicine

γδ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy

(2014) Alessandro Poggi et al.   Frontiers in Immunology

γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia

(2013) W Scheper et al.   LEUKEMIA

Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunity

(2013) Dieter Kabelitz et al.   OncoImmunology

γδ-T cells: an unpolished sword in human anti-infection immunity

(2012) Jian Zheng et al.   Cellular & Molecular Immunology

Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells

(2012) Andrea Knight et al.   CYTOTHERAPY

Human V 9V 2 T Cells Specifically Recognize and Kill Acute Myeloid Leukemic Blasts

(2012) J. Gertner-Dardenne et al.   JOURNAL OF IMMUNOLOGY

Human    T Lymphocytes Are Licensed for Professional Antigen Presentation by Interaction with Opsonized Target Cells

(2012) N. Himoudi et al.   JOURNAL OF IMMUNOLOGY

Tumor-promoting Versus Tumor-antagonizing Roles of γδ T Cells in Cancer Immunotherapy

(2012) Volker Kunzmann et al.   JOURNAL OF IMMUNOTHERAPY

Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas

(2012) Adriana Cordova et al.   PLoS One

Immunotherapy of acute myeloid leukemia based on γδ T cells

(2012) Julie Gertner-Dardenne et al.   OncoImmunology

Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens

(2010) Masashi Iwasaki et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Cutting Edge: TGF- 1 and IL-15 Induce FOXP3+    Regulatory T Cells in the Presence of Antigen Stimulation

(2009) R. Casetti et al.   JOURNAL OF IMMUNOLOGY

Immune Response of Human Propagated γδ-T-Cells to Neuroblastoma Recommend the Vδ1+ Subset for γδ-T-cell–based Immunotherapy

(2008) Karin Schilbach et al.   JOURNAL OF IMMUNOTHERAPY